Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Shares of Biogen BIIB, +1.85% rose 1.74% in morning trading after documents in a patent challenge brought by Mylan and Sawai show that Sawai and Biogen have settled.

Biogen shares rise on patent resolution with Sawai

Shares of Biogen BIIB, -2.81% fell about 3% in afternoon trading. The Cambridge, Mass.

Biogen shares fall 3%

Celgene

DaVita

Edwards Lifesciences

HCA Healthcare

Incyte

Pfizer

Teleflex

Health Care Select Sector SPDR Fund

DENTSPLY SIRONA

These are the health care stocks with the best value, fastest growth, and most momentum for November.

Top Health Care Stocks for November 2019

Ecopetrol

Lam Research

Micron Technology

Rio Tinto plc Sponsored

VMware

Several gurus are focusing on stocks whose Peter Lynch fair values are above their current prices, according to the GuruFocus All-in-One Screener.

6 Undervalued Stocks According to the Peter Lynch Value

AbbVie

Innoviva

Mylan

Novartis

Regeneron Pharmaceuticals

Theravance Biopharma

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline        

Alexion Pharma

Gildan Activewear

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs See Rising Tide in Short Interest (Nov 12)

Amgen

SunTrust initiated coverage on Biogen and Amgen on Tuesday, saying solid drug pipelines and growth opportunities in China will drive outperformance.

China seen as the next big growth area for biotechs Biogen and Amgen

The decision to reanimate an Alzheimer's disease program that died eight months earlier gave investors a lot to think about.

Here's Why Biogen Stock Shot Up 28% in October

Which stock wins in a head-to-head matchup between these two big biotechs?

Better Buy: Biogen vs. Celgene

Sell Biogen Going Into Its Aducanumab BLA Filing

Walgreens

New data on Biogen's formerly shelved Alzheimer's disease drug puts it on a path toward blockbuster status, but it will have to win regulatory approval first.

Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare Clinics

Biogen Is A Buy Regardless Of Aducanumab

Biogen Inc. BIIB, -0.43% said it plans to make a $100 million upfront payment to Samsung Bioepis to acquire the rights to commercialize biosimilar versions of Lucentis and Eylea, two blockbuster eye drugs.

Biogen ups investment in biosimilars

CAMBRIDGE, Mass., Nov.  06, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis®1 and SB15 referencing Eylea®2, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for its anti-TNF portfolio, including BENEPALITM (etanercept), FLIXABITM (infliximab) and IMRALDITM (adalimumab), in China. Biogen will also acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti-TNF portfolio in Europe.

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Federal regulators may buckle to public and political pressure to approve Biogen's experimental Alzheimer's drug, said Jefferies' Michael Yee.

FDA verdict on Biogen's Alzheimer's drug likely to be a 'political decision,' analyst says

With news that Biogen’s Alzheimer’s drug was allowed to reapply for possible FDA approval, Biogen stock skyrocketed. However, investors will want to carefully consider all angles before jumping onboard.

The Good, Bad, and Ugly for Biogen Stock

Investors were pleasantly surprised by an unexpected turnaround in aducanumab's clinical trial data, but how justified is the market's optimism?

What Should Investors Think of Biogen's Alzheimer's Drug Candidate?

Biotech company Biogen Inc (NASDAQ: BIIB)'s once-failed Alzheimer's drug, aducanumab, re-emerged Oct.

Cramer Makes The Case Why Biogen's Stock Could Double In Value

Alkermes

Biogen Inc. (NASDAQ: BIIB) and Alkermes PLC (NASDAQ: ALKS) announced an update from the U.S.Food and Drug Administration on Wednesday morning.

Multiple Sclerosis Treatment Wins Big FDA Approval

Biotechnology major Biogen (NASDAQ: BIIB) saw its stock soar by over 25% in Tuesday’s trading, after the company indicated that it intends to seek regulatory approval for its investigational treatment for early-stage Alzheimer’s disease.

How The Aducanumab Surprise Helped Biogen Stock

– VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability – – VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability –

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

Biogen Inc. BIIB, +0.66% and Alkermes PLC ALKS, +2.40% said Wednesday that U.S. Food and Drug Administration approved Vumerity for the treatment of relapsing forms of multiple sclerosis.

Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges

It’s trick-or-treat time, and an individual who claims to be a former member of Biogen’s (NASDAQ:BIIB) research and development team thinks investors who helped push the stock up 30% in the past week on news the company’s experimental drug for Alzheimer’s has been resurrected may be left holding the bag.

Analysts Like Biogen's Chances of Getting Alzheimer's Drug Approved

Biogen (NASDAQ:BIIB) shocked the biotechnology world last week with a surprise announcement that its Alzheimer’s drug aducanumab may be efficacious after all.

Biogen Alzheimer’s Case Shows Danger of Trials Killing Good Drugs

Arvinas Inc

Can these recent highfliers keep climbing?

News for Biogen Stock (BIIB)